Experienced HR executive with global tech background joins executive leadership team

908 Devices (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced that Michele Fournier has joined the company as Chief People Officer. Bringing more than thirty years of global human resources experience in corporate and consulting roles, Michele will lead human resource strategies, processes, and systems to optimize business and talent outcomes for 908 Devices.

In this new role, Michele will build a strong talent acquisition pipeline, promote inclusion and diversity in the workplace, and help shape and define employee career paths. Michele will apply her deep knowledge working in partnership with executive leaders to drive high performance and develop the people and growth strategies for the public company.

“As we continue to revolutionize chemical analysis and bring mass spec to the masses, Michele’s role will be pivotal to shape an engaged, inclusive and high-performing team and culture, poised for growth,” said Dr. Kevin J. Knopp, CEO of 908 Devices. “Michele brings the exact expertise we were looking for to ensure we can continue to attract and retain top talent as we expand and evolve as a public company.”

Prior to joining the company, Michele held a variety of senior HR leadership roles including executive vice president and chief human resources officer and corporate vice president, compensation, benefits and HRIS at Parexel International, a Clinical Research Organization in Newton, Massachusetts; and as corporate vice president of global human resources and corporate services at PTC, a Product Lifecycle Management technology company in Boston, Massachusetts. Michele earned her B.A. from the University of Michigan and is a Certified Compensation Professional (CCP).

Michele commented, “908 Devices attracted me with its dynamic and inventive team that’s committed to delivering excellence and cutting-edge technology. I’m excited to help the growing company assist forensic and life sciences customers in better navigating their workflows and draw life-saving research conclusions in labs and in the field.”

About 908 Devices

908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics, and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning. To learn more about 908 Devices, visit: https://908devices.com/.

Forward Looking Statements

This press release includes “forward looking statements,” including with respect to the future growth of the Company and the opportunity for the Company’s products. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the SEC which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005279/en/